Abstract |
In contrast with extensive information on the management of deep vein thrombosis of the lower extremities, little is known on the most appropriate treatment of the superficial vein thrombosis (SVT). In a multicenter, prospective, controlled, double-blind, double-dummy clinical trial, 164 consecutive patients with acute SVT of the great saphenous vein were randomized to receive the s.c. administration of either fixed prophylactic doses (2850 a-Xa IU) or body-weight adjusted therapeutic doses of nadroparin once daily for 1 month. The main study outcome was to compare the rate of asymptomatic and symptomatic extension of SVT and/or venous thromboembolic (VTE) complications during a 3-month follow-up period. Of the 81 patients randomized to the prophylactic doses, seven [8.6%; 95% confidence interval (CI), 3.5-17.0] developed SVT progression or VTE complications as compared with six of the 83 (7.2%; 95% CI, 2.8-15.1) allocated to the treatment group (absolute difference, 1.4; 96% CI, -6.9 to 9.7; P = 0.74). No patient in either group developed major bleeding. Our findings suggest that therapeutic doses of low-molecular-weight heparin, administered for 1 month in patients with SVT of the greater saphenous vein do not improve results obtained by prophylactic doses, administered for the same period, over a 3-month follow-up period.
|
Authors | P Prandoni, D Tormene, R Pesavento, Vesalio Investigators Group |
Journal | Journal of thrombosis and haemostasis : JTH
(J Thromb Haemost)
Vol. 3
Issue 6
Pg. 1152-7
(Jun 2005)
ISSN: 1538-7933 [Print] England |
PMID | 15946202
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Heparin, Low-Molecular-Weight
|
Topics |
- Aged
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Heparin, Low-Molecular-Weight
(administration & dosage)
- Humans
- Incidence
- Leg
(blood supply)
- Male
- Middle Aged
- Premedication
- Saphenous Vein
- Thromboembolism
(prevention & control)
- Treatment Outcome
- Venous Thrombosis
(complications, drug therapy)
|